Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

CNS tumours

5426 - Impact of WHO 2016 update and molecular markers in pleomorphic xanthoastrocytoma


09 Sep 2017


CNS tumours


Raees Tonse


Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366


R. Tonse, T. Gupta, E. Sridhar, J. Shastri, A. Jain, N. Bano, R. Jalali

Author affiliations

  • Radiation Oncology, Tata Memorial Centre, 400012 - Mumbai/IN


Abstract 5426


There is a relative paucity of data regarding outcomes of pleomorphic xanthoastrocytomas (PXA) particularly with respect to the impact of emerging molecular markers. We present our institutional experience of PXA and correlate their outcomes with various clinical and pathological factors.


Between 2006 to 2016, 37 patients with histologically verified PXA form the study cohort. All patients underwent maximal safe resection; those who had good resection, low MIB-1 index and young age were observed. Adjuvant radiotherapy was given in patients with atypical features on histology, high MIB-1 index and recurrence after first surgery or with significant residual disease. Patients diagnosed with anaplastic PXA were managed by multi-modality approach comprising maximal safe resection, radiotherapy and systemic therapy. BRAFV600E mutation testing was attempted in all 37 paraffin embedded tissue blocks. Progression free survival (PFS) and overall survival (OS) and potential prognostic factors affecting outcomes were analyzed.


Median age at diagnosis was 20 years (range 4–45). Tumors were predominantly in the temporal lobe and seizures were the most frequent symptom at presentation. Gross total resection (GTR) was achieved in 23 cases (62%), a subtotal resection (STR) in 13 cases (35%) and biopsy in one patient. At a median follow-up of 33 months, 3-year and 5-year OS was 80.2% & 74% respectively. Patients who underwent GTR had a better PFS as compared to those who underwent STR (3-year estimates 85.6% vs. 32.3%; p = 0.001). 10 patients (27%) were classified as having anaplastic PXA. PFS was significantly superior in PXA grade II as compared to the anaplastic PXA group (3-year estimates 80.2% vs. 32%; p = 0.007). Of the 27 patients where BRAF V600E testing was successful, 13 patients showed a mutation (48%). 3-year PFS & OS survival in BRAFV600E mutated patients was 51.9% & 76.9% compared to 73% & 75% in BRAFV600E non-mutated patients, respectively. No patient had an IDH1 mutation.


Anaplastic PXA has worse outcomes as compared to PXA grade II. This data may provide valuable insights and set as a benchmark for imparting targeted therapies.

Clinical trial identification

Legal entity responsible for the study



Brain Tumour Foundation of India


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.